Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide, and Topotecan in Drug-Resistant Tumor Cells

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 1160-1169

  Hu, YanPing ^a,b   Krishan, Awtar ^b   Nie, WeiJia ^b,c   Sridhar, Kasi S ^b   Mayer, Lawrence D ^a,c,d   Bally, Marcel ^a,c,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Celator Technologies Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CLONOGENIC ASSAY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; TUMOR CELL;

ACRIDINES; AGAR; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATALYSIS; CELL LINE, TUMOR; CELL NUCLEUS; CLINICAL TRIALS; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, SUPERHELICAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; HUMANS; INHIBITORY CONCENTRATION 50; PYRAZOLES; TOPOTECAN;

EID: 1042290309     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1044-3     Document Type: Article

References (32)

1. Adjei, A. A. Current status of pyrazoloacridine as an anticancer agent. Investig. New Drugs Review, 1791: 43-48, 1999.
2. Sebolt, J. S., Scavone, S. V., Pinter, C. D., Hamelehle, K. L., Von Hoff, D. D., and Jackson, R. C. Pyrazoloacridines, a new class of anticancer agents with selectivity agains solid tumors in vitro. Cancer Res., 47: 4299-4304, 1987.
3. Jackson, R., Sebolt, J. S., Shillis, J. L., and Leopold, W. R. The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Investig., 8: 39-47, 1990.
4. LoRusso, P., Wozniak, A. J., Polin, L., Cappa, D., Leopold, W. R., Werbel, L. M., Biernat, L., Dan, M. E., and Corbett, T. H. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res. 50: 4900-4905, 1990.
5. Sebolt, J. S., Leopold, W. R., Hamelehle, K. L., Pinter, C. D., and Plowman, J. Solid tumor selectivity of the 2-aminoalky-5-nitro-pyrazrolo(3, 4, 5-kl)acridines, a novel class of DNA-binding antitumor agents. Proc. Am. Assoc. Cancer Res., 27: 421, 1986.
6. Sebolt, J. S., Havlick, M., Hamelehle, K., Nelson, J., and Jackson, R. Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother. Pharmacol., 24: 219-224, 1989.
7. Cole, S. P. Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother. Pharmacol., 26: 250-256, 1990.
8. Grem, J. L., Politi, P. M., Berg, S. L., Benchekroun, N. M., Pael, M., Balis, F. M., Sinha, B. K., Dahut, W., and Allegra, C. J. Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. Biochem. Pharmcol., 51: 1649-1659, 1996.
9. Adjei, A. A., Charron, M., Rowinsky, E. K., Svingen, P. A., Miller, J., Reid, J. M., Sebolt-leopold, J., Ames, M. M., and Kaufmann, S. H. Effect of pyrazoloacridine (NSC 3666140) on DNA topoisomerases 1 and II. Clin. Cancer Res., 4: 683-691, 1998.
10. Grem, J. L., Harold, N., Keith, B., Chen, A. L., Kao, V., Takimoto, C. H., Hamilton, J. M., Pang, J., Pace, M., Jasser, G. B., Quinn, M. G., and Monahan, B. P. A Phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients. Clin. Cancer Res., 8: 2149-2156, 2002.
11. LoRusso, P., Foster, B. J., Poplin, E., McCormick, J., Kraut, M., Flaherty, L., Heilbrun, L. K., Valdivieso, M., and Baker, L. Phase 1 clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin. Cancer Res., 1: 1487-1493, 1995.
12. Rowinsky, E. K., Noe, D. A., Grochow, L. B., Sartorious, S. E., Bowling, M. K., Chen, T. L., Lubejko, B. G., Kaufinann, S. H., and Donehower, R. C. Phase 1 and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J. Clin. Oncol., 13: 1975-1984, 1995.
13. Zalupski, M. M., Philip, P. A., LoRusso, P., and Shields, A. F. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemother. Pharmacol., 40: 225-227, 1997.
14. Zalupski, M. M., Shields, A. F., Philip, P. A., Kraut, M., LoRusso, P., Heilbrun, L. K., and Vaitkevicius, V. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Investig. New Drugs, 16: 93-96, 1998.
15. Dodd, P. M., McCaffrey, J. A., Mazumdar, M., Icasiano, E., Higgins, G., Herr, H., and Bajorin, D. F. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. Investig. New Drugs, 18: 247-251, 2000.
16. Vuky, J., McCaffrey, J., Ginsberg, M., Mariani, T., Bajorin, D. F., Bosl, G. J., and Motzer, R. J. Phase II trial of pyrazoloacridine in patient with cisplatin-refractory germ cell tumors. Investig. New Drugs, 18: 265-267, 2000.
17. Kuebler, J. P., King, G. W., Triozzi, P., Moore, T., and Kraut, E. H. Phase II study of pyrazoloacridine in metastatic renal cell carcinoma. Investig. New Drugs, 19: 327-328, 2001.
18. Small, E. J., Fippin, L. J., and Whisenant, S. P. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Investig., 16: 456-461, 1998.
19. Plaxe, S. C., Blessing, J. A., Bookman, M. A., and Creasman, W. T. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecol. Oncol. Group study. Gynecol. Oncol., 84: 32-35, 2002.
20. Plaxe, S. C., Blessing, J. A., Morgan, M. A., and Carlson, J. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecol. Oncol. Group study. Am. J. Clin. Oncol., 25: 45-47, 2002.
21. Greco, W. R., Bravo, G., and Parsons, J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev., 47: 331-385, 1995.
22. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
23. Ellis, A. L., Nowak, B., Plunkett, W., and Zwelling, L. A. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother. Pharmacol., 34: 249-256, 1994.
24. Politi, P. M., Berg, S. L., Balis, F. M., Poplack, D. G., Allegra, C. J., and Grem, J. L. Cytotoxicity and cell-associated levels of pyrazoloacridine in human multidrug resistant tumor cell lines. Proc. Am. Assoc. Cancer Res., 33: 524, 1992.
25. Adjei, A. A., Budihardjo, I. I., Rowinsky, E. K., Kottke, T. J., Svingen, P. A., Buckwalter, C. A., Grochow, L. B., Donehower, R. C., and Kaufmann, S. H. Cytotoxic synergy between pyrazoloacridine (NSC 3666140) and cisplatin in vitro: inhibition of platinum-DNA removal. Clin. Cancer Res., 3: 761-760, 1997.
26. Buckwalter, C. A., Lin, A. H., Tanizawa, A., Pommier, Y. G., Cheng, Y. C., and Kaufmann, S. H. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res., 56: 1674-1681, 1996.
27. Smith, P. J., and Soues, S. Multilevel therapeutic targeting by topoisomerase inhibitors. Br. J. Cancer, 23: S47, 1994.
28. Doroshow, J. H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res., 43: 460-472, 1983.
29. Chow, K. C., King, C. K., and Ross, W. E. Abrogation of etoposide-mediated cytotoxicity by cycloheximide. Biochem. Pharmacol., 37: 1117-1122, 1988.
30. Sinha, B. K., and Eliot, H. M. Etoposide-induced DNA damage in human tumor cells: requirement for cellular activating factors. Biochim. Biophys. Acta, 1097: 111-116, 1991.
31. Eng, W. K., McCabe, F. L., Tan, K. B., Mattern, M. R., Hofmann, G. A., Woessner, R. D., Hertzberg, R. P., and Johnson, R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol. Pharmacol., 38: 471-480, 1990.
32. Adjei, A. A., Charron, M., Rowinsky, E. K., Svingen, P. A., Miller, J., Reid, J. M., Sebolt-Leopold, J., Ames, M. M., and Kaufmann, S. H. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin. Cancer Res., 4: 683-691, 1998.